10 November 2020 - The U.S. Department of Health and Human Services today announced plans to allocate initial doses of Eli Lilly and Company’s investigational monoclonal antibody therapeutic, bamlanivimab, which received emergency use authorisation from the U.S. FDA November 9 for the treatment of non-hospitalised patients with mild or moderate confirmed cases of COVID-19.

On 28 October, the federal government announced a purchase of 300,000 doses of bamlanivimab. HHS will allocate these doses to state and territorial health departments which, in turn, will determine which healthcare facilities receive the infusion drug. 

The federal government can purchase up to 650,000 additional doses if needed through 30 June 2021, for distribution across the country.

Read HHS press release